Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.

PloS one - 1 Jan 2023

Ponnuvel Suresh, Prakash Arul, Steve Runal John, Doss George Priya, Goel Ashish, Zachariah Uday George, Eapen Chundamannil Eapen, Rebekah Grace, Kannangai Rajesh, Fletcher Gnanadurai John, Abraham Priya

Abstract excerpt

BACKGROUND: In the economy of therapeutic monitoring, an affordable viral marker is essential in the era of direct-acting antivirals (DAAs). We elucidated the kinetics of HCVcAg to delineate its precise role in monitoring therapeutic response. METHODS: In this longitudinal study, 3208 patients were tested for HCV RNA. A total of 423 patients were started on DAAs. Treatment response and kinetics of HCVcAg/RNA were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C Antigens

Share to Hepatitis C, Chronic

Share to Longitudinal Studies

Share to Recurrence

Share to RNA, Viral

Source

Open in PubMed Open full text

Identifiers

PMID: 36800372
DOI: 10.1371/journal.pone.0282013
PMCID: PMC9937470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs.PMID 36800372Read ↗

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.Semantic proximity Read ↗

Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients.Semantic proximity Read ↗

Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.Semantic proximity Read ↗

Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antiviralsSemantic proximity Read ↗

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.Semantic proximity Read ↗

The importance of HCV RNA measurement for tailoring treatment duration.Semantic proximity Read ↗

Hepatitis C Virus (HCV) diagnosis, epidemiology and access to treatment in a UK cohortSemantic proximity Read ↗

DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.Semantic proximity Read ↗

Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.Semantic proximity Read ↗

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.Semantic proximity Read ↗

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.Semantic proximity Read ↗

Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.